Home Team Services Contact
Akhilesh Poddar

Akhilesh Poddar, the founder of Highbrow Capital, had an illustrious career spanning approximately a decade with one of the top international investment bank where he worked on several landmark transactions (both international and domestic) across equity capital market, mergers & acquisition and private equity.

He is a Chartered Accountant (top 50 rank in both Foundation and Final) and a Chartered Financial Analyst (gold medallist) from ICFAI.

Some of the most prominent transactions with which Akhilesh was associated are:

Mergers & Acquisitions Advisory

He was involved in execution of several landmark M&A Advisory transactions including:

   - Petrochina on US$2.5 billion acquisition of 50% stake in CNPC’s international oil and gas assets;
   - PTT’s on US$1 billion acquisition of a stake in restructured Thai Petroleum Industries;
   - Prolec-GE on US$76 million acquisition of Indo-Tech Transformers;
   - Orchid on US$400 million sale of its injectables business to Hospira;
   - Dabur Pharma on US$35 million sale of non-oncology business to Alembic Pharma;
   - Advising a leading Indian pharmaceutical companies on potential US$6 billion acquisition of Merck’s Generics Business;
   - Advising a leading unlisted CRO player in India on potential sale of the Company.

Private Equity Advisory

He was involved in execution of several Private Equity transactions including:

   - Advising Apax on US$105 mm investment in Apollo Hospitals;
   - Advising All Cargo on US$60 million capital raise fromBlackstone;
   - Advising Citi on sale of their minority position in an unlisted Indian company to a leading Indian PE investor;
   - Advising a leading power company on pre-IPO placement to private equity investors;
   - Advising a retail company on restructuring and placement of equity to private equity investors.

Equity Capital Markets

He worked on several landmark IPOs by Indian corporates including US$3.4 billion IPO of Coal India (largest IPO in India till date); US$750 million IPO of Oil India; US$2.2 billion IPO of DLF; US$212 million IPO of Puravankara; US$100 million IPO of Fortis.

He was also engaged in execution of several follow-on capital market offering by Indian corporates including:

   - Follow-on Offering: NTPC (US$1.8 billion) and Andhra Bank (US$175 million);
   - QIPs: Glenmark Pharmaceuticals (US$85 million) and CESC (US$150 million);
   - Rights Issue: Suzlon Energy (US$280 million);
   - Block Trades: Suzlon Energy (US$300 million), Apollo Hospitals (US$60 million), GAIL (US$127 mm Block) and ONGC (US$815 mm);
   - ADRs: Sterlite Industries (US$2 billion) and Dr. Reddy’s (US$230 million);
   - GDRs: Suzlon (US$108 million), Gateway Distriparks (US$85 million) and IL&FS Investsmart (US$100 million);
   - FCCBs: Plethico Pharmaceuticals (US$75 million); Tata Motors (US$490 million and US$100 million) and Orchid (US$85 million GDR+ FCCB).

Home | Team | Services | Contact

© Copyright Highbrow Capital. All Rights Reserved.